Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients
Status:
Completed
Trial end date:
2020-04-21
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to
evaluate the safety and efficacy of Q301 Cream vs. vehicle in adolescent and adult subjects
with mild to moderate AD. Study drug (Q301 Cream or vehicle) will be administered topically
twice a day for 8 consecutive weeks.